Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Metacare Co., Ltd. is a South Korean pharmaceutical company primarily engaged in the development and manufacturing of generic drugs and over-the-counter medications. The company has a significant presence in the Asia-Pacific region, with a diverse product portfolio that includes cardiovascular and anti-diabetic medications, which are critical given the rising prevalence of chronic diseases in these markets.
Metacare generates revenue primarily through the sale of generic pharmaceuticals, leveraging its cost-effective production capabilities to maintain competitive pricing. The company benefits from strong relationships with healthcare providers and distributors across Asia, providing it with a stable revenue base. Its focus on R&D allows it to expand its product offerings and adapt to changing market demands.
Regulatory approvals for new generic drugs
Market share changes in key therapeutic areas such as diabetes and cardiovascular health
Pricing pressures from competitors
Changes in healthcare policies affecting drug pricing
Regulatory changes impacting drug approval processes
Technological advancements in drug development that may outpace Metacare's capabilities
Intensifying competition from both local and international generic drug manufacturers
Potential for price wars in key therapeutic segments
High capital expenditures leading to negative free cash flow
Low net margin indicates vulnerability to operational inefficiencies
moderate - The company's performance is somewhat tied to healthcare spending, which can be affected by GDP growth and consumer spending patterns.
Low - Metacare's business is not heavily reliant on debt financing, but higher interest rates could impact consumer spending on healthcare products.
minimal - The company has a manageable debt-to-equity ratio of 0.44, indicating limited reliance on credit for operations.
value - Investors may be drawn to the low valuation metrics, particularly the price-to-sales ratio of 0.6x.
high - The stock has exhibited significant price volatility, with a 1-year return of -60.3%.
